Bicycle Therapeutics plc — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing also reports fourth-quarter results. This is a clinical-stage biotechnology company; it had no approved products and generated no product-sale revenue.
Business context and pipeline
Bicycle develops synthetic bicyclic peptide medicines using a proprietary screening platform. Its internal programs focus on oncology: BT1718 (MT1-MMP-targeting toxin conjugate) was in a CRUK-sponsored Phase I/IIa trial; BT5528 (EphA2-targeting) was in a company-sponsored Phase I/II trial; BT8009 (Nectin-4-targeting) and BT7480 (Nectin-4/CD137 immune agonist) remained in preclinical or IND-enabling work. Collaborations address other therapeutic areas.
Financial performance and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Collaboration revenue | $13.8 million | $7.1 million |
| Research and development expense | $25.5 million | $20.8 million |
| General and administrative expense | $14.6 million | $8.1 million |
| Operating loss | $26.3 million | $21.7 million |
| Net loss | $30.6 million | $21.8 million |
| Net loss per share | $2.77 | $49.78 |
FY2019 collaboration revenue rose $6.7 million, mainly because Sanofi program options expired, prompting recognition of $10.0 million of previously deferred revenue; research-service revenue from Sanofi decreased. The $5.4 million net other expense was primarily a noncash remeasurement of warrant liability before the IPO; the liability was converted to equity at the IPO.
Fourth-quarter 2019 collaboration revenue was $5.3 million, operating expenses were $10.0 million, and net loss was $4.4 million, compared with revenue of $1.1 million, expenses of $8.6 million, and net loss of $6.6 million in Q4 2018.
Operating cash use was $28.6 million in 2019; investing cash use was $1.6 million, and financing provided $58.4 million, chiefly from the IPO. Cash at year-end was $92.1 million, working capital $95.3 million, and total liabilities $17.0 million. The company reported no debt outstanding. Management expected available cash to fund operations and capital expenditure requirements for at least 12 months from the March 10, 2020 filing date, while cautioning that estimates may prove wrong. No gross-margin figure is applicable to product sales, which had not begun.
Changes, outlook and key risks
- Losses widened as R&D and administrative spending increased. R&D expense growth reflected broader discovery work, BT8009 and immune-agonist development, and increased staffing; G&A growth included public-company costs.
- Management expected higher expenses as clinical and preclinical programs advance. It anticipated CRUK expansion cohorts for BT1718 in 2020, further BT8009 and BT7480 development, and BT8009 clinical entry targeted for 2020. These are plans, not assured outcomes.
- BT1718 was described as generally tolerable on the once-weekly schedule, with manageable adverse events; early tumor biopsies showed DM1 delivery in two of three patients. These limited, preliminary observations do not establish efficacy. Reported treatment-related events included anemia, gastrointestinal symptoms, fatigue, liver-enzyme elevations and peripheral neuropathy.
- Sanofi terminated its collaboration in 2019. Bicycle said it was assessing whether to advance the returned sickle-cell and hemophilia work internally, seek a partner or stop it.
- After year-end, a Dutch appeals court ruled that Pepscan could terminate a patent license and issued a worldwide injunction against BicycleRD exploiting specified Pepscan patents and related know-how, with a €25,000 daily fine for noncompliance. BicycleRD said it would comply and appeal. The dispute may affect programs that used the licensed scaffold, including BT1718; the company said the injunction applies only to BicycleRD.
- A February 2020 Genentech collaboration was a subsequent event, not FY2019 revenue: it provided for a $30 million upfront payment and potential milestones and royalties. The company also flagged uncertainty from Brexit, currency movements, third-party manufacturing reliance and the coronavirus outbreak.
- The company reported that it remediated a previously disclosed material weakness in warrant-valuation controls during 2019; management concluded disclosure controls were effective at year-end. The filing also notes restatements of earlier-period financial statements related to that weakness.
Investor verification priorities
- Confirm cash burn, projected runway and the timing and terms of any additional financing needs.
- Track clinical-trial enrollment, dose escalation, safety, biomarker findings and evidence of patient benefit for BT1718 and BT5528; distinguish preliminary data from validated outcomes.
- Assess the scope and consequences of the Pepscan injunction and appeal, including any impact on BT1718 or other licensed-scaffold assets.
- Verify the status and economics of the Genentech agreement and the company’s ability to convert collaboration work into milestones, royalties or sustained revenue.
- Monitor the post-Sanofi disposition of returned programs and the cost, timing and execution risks of advancing the broader pipeline.
- Review the audited financial statements and notes for collaboration-revenue recognition, warrant-related expense, lease obligations and any updates to liquidity or contingencies.